Healthy Volunteers Clinical Trial
Official title:
Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by Peripheral Intravenous Analysis (PIVA) Technology
Verified date | March 2021 |
Source | Baxter Healthcare Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Non-invasive sensors have been used in research in the United States (US) to aid in the assessment of a subject's heart rate (HR), respiratory rate (RR) and fluid volume status. This estimate and its trended value over time, when used along with clinical signs and symptoms and other subject test results, can aid in the process of reaching a diagnosis and formulating a therapeutic plan when abnormalities of volume status, or RR are suspected. Non-invasive sensors like the Peripheral IntraVenous Analysis (PIVA) sensor under development by Baxter and the Deltran blood pressure (BP) transducer, capture waveforms created by physiological mechanisms such as blood flow and breathing. An algorithm is then applied to the captured waveform to give clinicians an idea of hemodynamic (volume) status, and RR. In this study, the functional robustness (e.g., subjects sitting, elevated leg positions, etc.) of the PIVA algorithm/technology will be demonstrated by evaluating the impact of various common interventions on the venous pressure signal. All subjects will undergo 33 interventions expected to take approximately 4 - 6 hours.
Status | Terminated |
Enrollment | 26 |
Est. completion date | March 21, 2020 |
Est. primary completion date | March 21, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Has reviewed, understood and signed an informed consent. - Age between 18-55 years. - Body mass index between 18.5-35 kg/m2 with a minimum weight of 45 kg. - Willing and able to comply with study procedures and duration. - Subjects wearing any type of nail polish and/or acrylic nails must be willing to remove them prior to admission. Exclusion Criteria: - Female subjects who are pregnant. - Subjects who are currently participating in, or have within the past 30 days participated in, another interventional clinical study or have used an investigational device or drug within the past 30 days. - Subjects with known respiratory conditions including but not limited to: - uncontrolled / severe asthma - flu / influenza - pneumonia / bronchitis - shortness of breath / respiratory distress - respiratory or lung surgery - emphysema, chronic obstructive pulmonary disease, lung disease - any other health condition that the Principal Investigator thinks can affect respiratory health - Subjects with self-reported heart or cardiovascular conditions including but not limited to: - hypertension - history of cardiovascular surgery - chest pain (angina) - heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia - previous heart attack - blocked artery - unexplained shortness of breath - congestive heart failure - history of stroke - transient ischemic attack - carotid artery disease - myocardial ischemia - myocardial infarction - restrictive or constrictive cardiomyopathy - congenital heart disease other than patent foramen ovale, repaired atrial or ventricular septal defect - any type of cardiac valve disease - history of cardiac arrhythmias - Self-reported health conditions as identified in the Health Assessment Form - diabetes - uncontrolled thyroid disease - kidney disease / chronic renal impairment - history of seizures (except childhood febrile seizures) - epilepsy - history of unexplained syncope - history of migraine attacks in the last 3 months - head injury within the last 2 months - cancer / chemotherapy - other known health condition should be considered upon disclosure in health assessment form - history of substance abuse or addiction to alcohol and or drugs within the last 12 months - Subjects with self-reported bleeding disorders including but not limited to: - hemophilia - von Willebrand disease - history of blood clots - history of bleeding problems - bruises easily with everyday activities - Subjects taking prescription blood thinners (like aspirin, clopidogrel, dipyridamole, or ticlopidine). - Subjects may be excluded at the discretion of the Investigator. |
Country | Name | City | State |
---|---|---|---|
United States | Baxter Investigational Site | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
Baxter Healthcare Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Signal Quality Index (SQI) Score by Supine, Sitting, Standing Body Positions | Ranking of subject body positions (supine, sitting, standing) based upon their impact on the venous waveform signal, from best to worst, based on the PIVA algorithm-derived SQI. Score on the scale include 0=no signal, 1=poor signal, 2=good signal. The highest percentage of time with good signal quality will be the best ranked position, and the lowest percentage of time with good signal quality will be the worst ranked position. | End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes) | |
Secondary | Agreement between PIVA algorithm-derived RR and RR measured with Capnography at Baseline | The difference of the PIVA algorithm-derived outcomes to their comparators (Capnography) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. Capnography is the monitoring of the concentration or partial pressure of carbon dioxide in the respiratory gases. | End of 10 minute baseline | |
Secondary | Agreement between PIVA algorithm-derived RR and RR measured with Nellcor bedside monitor at Baseline | The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. | End of 10 minute baseline | |
Secondary | Agreement between PIVA algorithm-derived RR and RR measured with manual counting | The manual count value will be an average of the 2 minutes then the count is taken over. The difference of the PIVA algorithm-derived outcomes to their comparators (manual) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. | End of 10 minute baseline | |
Secondary | Agreement between PIVA algorithm derived PR and PR measured with Nellcor bedside monitor at Baseline | The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. | End of 10 minute baseline | |
Secondary | Change in PIVA algorithm derived volume index between supine and passive leg raising positions | The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum. | End of Interventions #15 (supine for 5 minutes) and #18 (passive leg raise for 5 minutes) | |
Secondary | Change in PIVA algorithm derived volume index between supine and standing positions | The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum. | End of interventions #15 (supine for 5 minutes) and #19 (standing for 5 minutes) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |